加速康复外科 (ERAS) 指南为术后患者提供了显着的益处。护理包结合了各种循证治疗和护理措施来管理难治性临床疾病。因此，我们旨在评估 ERAS 措施和护理组合，以减少电视辅助胸腔手术 (VATS) 肺叶切除术相关的术后并发症并促进患者康复。作为一项回顾性研究，本研究纳入了 120 例非小细胞肺癌患者根据病历系统中患者的术后护理方式将患者分为对照组和观察组。其中，2018年1月至2019年1月收治的60例患者纳入对照组，2022年1月至2023年1月收治的60例患者纳入观察组。对照组接受常规护理（非ERAS组），观察组遵循基于ERAS指南的捆绑护理策略（ERAS组）。收集的数据包括 ERAS 组和非 ERAS 组患者的基线特征、临床参数和术后参数。所有患者的临床资料均来自医院病历系统。ERAS组与非ERAS组在性别、年龄、肿瘤淋巴结转移（TNM）分期、吸烟、饮酒等方面差异无统计学意义（p>0.05）。同样，ERAS 组和非 ERAS 组之间的心脏射血分数 (≥50%)、1 秒用力呼气量 % (FEV1%) 用力肺活量 (FVC)、淋巴细胞、中性粒细胞 (%) 和肿瘤直径也没有观察到显着差异。 -ERAS 组（p > 0.05）。相比之下，FVC、FEV1%、肺一氧化碳单次呼吸弥散能力 (DLCO SB)、白蛋白、C 反应蛋白、白细胞、单核细胞、淋巴细胞 (%)、血红蛋白和中性粒细胞之间存在显着差异。 ERAS 组和非 ERAS 组 (p < 0.05)。此外，受试者工作特征 (ROC) 分析表明，白细胞、DLCO、C 反应蛋白 (CRP)、FEV1%、单核细胞、淋巴细胞 (%)、中性粒细胞 (%) 和体重指数 (BMI) 是 ERAS 的重要预测因子。使用白细胞 >12.5、FEV1% >112.9、单核细胞 >16.8 (109/L) 和中性粒细胞 >11.6 的截止值，接受 VATS 肺叶切除术的患者更有可能快速康复。当 ERAS 采取综合护理措施时，拔管时间可缩短至 5.5 天以内，视觉模拟评分 (VAS) 评分可缩短至 3.5 分以下，术后住院时间可缩短至 10.5 天以下。 ERAS 管理措施基于综合护理可以显着改善接受 VATS 肺叶切除术患者的预后，减少术后并发症，并加速安全康复。此外，它们还可以大大缩短住院时间，降低总体医疗费用，减轻社会和家庭负担。这些显着差异可能与白细胞、FEV1%、单核细胞和中性粒细胞等因素有关。

Enhanced recovery after surgery (ERAS) guidelines provide significant benefits for patients after surgery. Care bundles combine various evidence-based treatments and care measures for managing refractory clinical diseases. Therefore, we aimed to evaluate the ERAS measures and care bundles to reduce post-operative complications associated with video-assisted thoracic surgery (VATS) lobectomy and promote patients' recovery.As a retrospective study, this study included 120 non-small cell lung carcinoma patients, who were divided into a control group and an observation group according to the post-operative care methods of the patients in the medical record system. Among them, sixty patients, admitted from January 2018 to January 2019, were included in the control group, and 60 patients, admitted from January 2022 to January 2023, were included in the observation group. The control group received routine care (non-ERAS group), and the observation group followed the bundles of care strategy based on ERAS guidelines (ERAS group). Data collected included baseline characteristics, clinical parameters, and post-operative parameters of patients in the ERAS and non-ERAS groups. The clinical data of all patients came from the hospital medical record system.There were no significant differences in gender, age, tumor node metastasis (TNM) stages, smoking, and drinking between the ERAS and non-ERAS groups (p > 0.05). Similarly, no significant differences were observed in Cardiac Ejection fraction (≥50%), forced expiratory volume in 1 sec % (FEV1%) forced vital capacity (FVC), Lymphocyte, Neutrophils (%), and Tumor diameter between the ERAS and non-ERAS groups (p > 0.05). In contrast, significant differences were found in FVC, FEV1%, diffusing capacity of the lungs for carbon monoxide single breath (DLCO SB), Albumin, C-reactive protein, Leukocyte, Monocytes, Lymphocyte (%), Hemoglobin, and Neutrophils between the ERAS and non-ERAS groups (p < 0.05). Furthermore, Receiver Operating Characteristic (ROC) analysis indicated that Leukocytes, DLCO, C-reactive protein (CRP), FEV1%, Monocytes, Lymphocytes (%), Neutrophils (%), and Body Mass Index (BMI) were essential predictors of ERAS. Using cutoff values of Leukocytes >12.5, FEV1% >112.9, Monocytes >16.8 (109/L), and Neutrophils >11.6, patients undergoing VATS lobectomy were more likely to experience a quick recover. When ERAS measures integrated bundles of care, the extubation time can reduced to less than 5.5 days, the visual analogue scale (VAS) score to less than 3.5, and the post-operative hospital stay to less than 10.5 days.ERAS management measures based on bundles of care can significantly improve the prognosis of patients undergoing VATS lobectomy, reduce post-operative complications, and accelerate safe rehabilitation. Furthermore, they can greatly shorten hospital stays, lower overall healthcare costs, and alleviate social and family burdens. These significant differences may be related to factors such as Leukocytes, FEV1%, Monocytes, and Neutrophils.